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I n several large-scale clinical trials,  anti-vascular endothelial growth factor (VEGF) therapy has been 
shown to be an effective and safe treatment for macular 
edema (ME) due to branch retinal vein occlusion 
(BRVO).  Thus,  anti-VEGF therapy is currently the 
first-line treatment for ME due to BRVO [1-6].  
However,  one major problem with this therapy is that a 
suitable injection protocol has not yet been established 
[7].  One reason for this problem is that the required 
frequency of anti-VEGF injections differs greatly among 
individual BRVO cases.  While spontaneous remission 
is reported to occur in 18-41% of cases of ME due to 
BRVO [8 , 9],  a reported 50% of eyes still require anti-
VEGF injections for ME after 4 years [8].  Many large-
scale studies have used a protocol of monthly injections 
of anti-VEGF agents for 6 months followed by pro re 
nata (PRN) injections.  However,  monthly injections 
may result in overtreatment for patients who do not 
require frequent injections of anti-VEGF agents,  while 
a PRN regimen may result in undertreatment for 
patients who do require more frequent injections.  
Moreover,  both a monthly fixed regimen and a monthly 
PRN regimen can cause a significant health care burden,  
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To investigate the effectiveness of a treat-and-extend regimen (TAE) of intravitreal ranibizumab injections 
(IVR) for macular edema (ME) due to branch retinal vein occlusion (BRVO).  We retrospectively examined 35 
eyes of 35 patients with ME due to BRVO who underwent TAE for 1 year.  Patients whose treatment interval 
extended to 12 weeks were switched to a pro re nata regimen (PRN; TAE to PRN group),  while TAE was con-
tinued for patients whose treatment interval was less than 12 weeks (continued TAE group).  Changes in 
best-corrected visual acuity (BCVA),  central retinal thickness (CRT),  and predictive factors for inclusion in the 
TAE to PRN group were analyzed.  BCVA and CRT both improved significantly at 1 year compared with base-
line (p< 0.001).  Sixteen eyes (45.7%) were included in the TAE to PRN group,  while 19 eyes (54.3%) were 
included in the continued TAE group.  BCVA in the TAE to PRN group was significantly better than that in the 
continued TAE group at 1 year (p= 0.047).  BCVA at baseline and macular BRVO were significant predictive 
factors for inclusion in the TAE to PRN group.  TAE was effective for improving BCVA and CRT.  The TAE to 
PRN group showed significantly better prognosis.
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and frequent anti-VEGF injections may lead to the pro-
gression of geographic atrophy in age-related macular 
degeneration [7 , 10].  Therefore,  individualized rather 
than uniform regimens could minimize the number of 
anti-VEGF injections and clinic visits and thus reduce 
patient burden.
A treat-and-extend regimen (TAE) is an individual-
ized regimen that aims to decrease the number of injec-
tions and visits to the clinic by determining an optimal 
treatment interval [11-13].  A TAE regimen entails 
adjustment of the treatment interval according to the 
occurrence/nonoccurrence of relapse in order to ascer-
tain the maximum treatment interval during which 
there has been no relapse for every individual.  TAE is a 
regimen primarily used in anti-VEGF therapy for 
age-related macular degeneration,  but it is also thought 
to be effective in anti-VEGF therapy for treating ME due 
to BRVO [14].  However,  to the best of our knowledge,  
there has been only one report on the use of anti-VEGF 
therapy for treating ME due to BRVO using a TAE reg-
imen [14].  Therefore,  more knowledge is needed 
regarding the efficacy of this treatment method.
In the present study,  we retrospectively examined 
35 eyes of 35 patients with treatment-naïve ME due to 
BRVO who underwent TAE for 1 year.  We investigated 
the efficacy of TAE with respect to best-corrected visual 
acuity (BCVA; logarithm of the minimal angle of reso-
lution [logMAR]),  central retinal thickness (CRT),  and 
the number of intravitreal ranibizumab injections for 
treating ME due to BRVO.
Patients and Methods
Study design and patients. We retrospectively 
reviewed the medical records of 35 eyes of 35 consecu-
tive patients with treatment-naïve ME due to BRVO.  
The patients were treated with intravitreal injections of 
ranibizumab (0.5 mg; Lucentis,  Genentech/Novartis) 
using a TAE regimen,  described below,  for at least one 
year at Okayama University Graduate School of 
Medicine,  Dentistry and Pharmaceutical Sciences from 
October 2013 to November 2014.  This study was 
approved by the Institutional Review Board of Okayama 
University Graduate School of Medicine,  Dentistry and 
Pharmaceutical Sciences (approval No. 1506-043) and 
was conducted in accordance with the tenets of the 
Declaration of Helsinki.  Each patient was informed of 
the risks and benefits of treatment and gave written 
informed consent.
Ophthalmological examination. All patients 
underwent comprehensive ophthalmologic examina-
tions at all visits,  including measurement of best-cor-
rected visual acuity (BCVA) with refraction using the 
5-m Landolt C acuity chart and indirect and contact 
lens slit lamp biomicroscopy.  Patients’ BCVAs were 
recorded as decimal values and converted to logarithm 
of the minimal angle of resolution (logMAR) units for 
statistical analysis.  Diagnoses of ME due to BRVO were 
based on the results of fundus examinations,  fluores-
cein angiography (TRC50DX; Topcon Medical 
Systems,  Tokyo,  Japan),  and spectral-domain optical 
coherence tomography (SD OCT; Cirrus: Carl Zeiss 
Meditec,  Jena,  Germany; DRI OCT-1 Atlantis :  
Topcon Medical Systems).  We defined ME as central 
retinal thickness (CRT) greater than 300 μm,  as deter-
mined by OCT.  Patients with a history of thromboem-
bolic events were excluded from this study.
Treat-and-extend regimen. Intravitreal injec-
tions of ranibizumab were administered to all patients,  
with slight modifications to the TAE as described in the 
report of Rush et al.  [14].  Briefly,  the patients were 
examined and injected with ranibizumab every 4 weeks 
until no sign of active disease was found.  If there was 
no sign of active disease,  a new injection was given,  
and the period to the next treatment was extended by 4 
weeks at a time to a maximum interval of 12 weeks.  If 
an examination revealed any sign of recurrence,  the 
interval was shortened by 2 weeks at a time until the 
disease was considered to be inactive.  Patients whose 
treatment interval was extended to 12 weeks were sub-
sequently switched from TAE to a PRN regimen and 
were classified as belonging to the “TAE to PRN group”.  
After switching to PRN,  the first treatment interval was 
set to 12 weeks,  and the subsequent treatment interval 
was set to 4 weeks.  In contrast,  the TAE regimen was 
continued for patients whose treatment interval was less 
than 12 weeks,  and these patients were classified as 
belonging to the “continued TAE group”.
Patients who demonstrated a non-perfusion area of 
at least 10 optic discs area (DA) at baseline following 
fluorescein angiography underwent retinal photocoag-
ulation.
Outcome measures. The main outcome measures 
were the number of intravitreal injections of ranibi-
zumab and clinic visits during one year as well as 
changes in BCVA and CRT.  We also assessed several 
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prognostic variables for their ability to predict inclusion 
in the TAE to PRN group.  These variables included age,  
sex,  time from onset of BRVO to initial injection,  
BCVA,  CRT,  major or macular BRVO [15 , 16],  pres-
ence of a non-perfusion area over 10 optic DA,  pres-
ence of serous retinal detachment,  and history of 
hypertension.
Statistical analysis. Best-corrected visual acuity 
at baseline and at 1 year were compared using a paired 
t-test.  Both BCVA and CRT were compared at baseline,  
one month,  6 months,  and 1 year using a one-way 
ANOVA with a Bonferroni correction.  Predictive vari-
ables for inclusion in the TAE to PRN group were ana-
lyzed by multiple logistic regression analysis.  P values 
less than 0.05 were considered significant.  All statistical 
analyses were performed using SPSS version 22.0 for 
Windows (IBM,  Armonk,  NY,  USA).  Data are pre-
sented as the mean ± standard deviation.
Results
Thirty-five eyes of 35 Japanese patients were included 
in this study.  Baseline characteristics of these patients 
are shown in Table 1.  Fig. 1 shows the breakdown of 
therapeutic processes of all patients during the one year 
study period.
Nineteen eyes (54.3%) were of patients whose treat-
ment interval was less than 12 weeks,  and their TAE 
regimen was continued.  These patients were classified 
as the continued TAE group.  In contrast,  16 eyes 
(45.7%) were of patients whose treatment interval was 
extended to 12 weeks,  and these were subsequently 
switched to a PRN regimen.  These patients were classi-
fied as the TAE to PRN group.  Of the 16 eyes in the 
TAE to PRN group,  12 eyes (75.0%) did not demon-
strate relapsed ME during the PRN period,  and further 
treatment was unnecessary.  The remaining 4 eyes 
(25.0%) did demonstrate relapsed ME during the PRN 
period and required further treatment.
As shown in Fig. 2,  mean BCVA (logMAR) had 
improved significantly at 1,  6 and 12 months (0.21 ±  
0.21,  0.16 ± 0.22,  and 0.09 ± 0.22,  respectively) when 
compared with baseline (0.41 ± 0.33,  all p < 0.001,  one-
way ANOVA with a Bonferroni correction),  and BCVA 
at 1 year was significantly better in the TAE to PRN 
group compared to that in the continued TAE group 
(0.01 ± 0.11 and 0.16 ± 0.26,  respectively; p = 0.047,  
unpaired t-test; Table 2).
As shown in Fig. 3,  mean CRT decreased signifi-
cantly at 1,  6,  and 12 months (269.4 ± 50.1 μm,  289.1 
± 85.2 μm,  and 271.3 ± 67.7 μm,  respectively) when 
compared with baseline (445.1 ± 113.2 μm,  all p < 0.001,  
one-way ANOVA with Bonferroni test).  No significant 
difference was observed in CRT between the TAE to 
PRN group and the continued TAE group at 1 year 
(273.9 ± 85.2 and 269.0 ± 51.0,  respectively; p = 0.833,  
unpaired t-test; Table 2).
Among all patients,  the mean number of injections 
and the mean number of clinic visits in 1 year were 
6.0 ± 2.1 and 6.8 ± 1.6,  respectively (Table 2).  In the 
TAE to PRN group,  the mean number of injections and 
the mean number of clinic visits in 1 year were 4.2 ± 0.4 
and 6.1 ± 0.8,  respectively.  These numbers were both 
significantly lower than in the continued TAE group,  
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Table 1　 Baseline patient characteristics
Cases 35
Age (years) 71.2±11.5
Sex (male/female) 15/20
Time period from onset of BRVO to initial injection 
(months) 1.9±1.6
Major BRVO/Macular BRVO 22/13
NPA≥10DA (eyes (%)) 14 (40.0)
SRD (eyes (%)) 15 (42.9)
Hypertension (eyes (%)) 22 (62.9)
Data are presented as the mean ± standard deviation.
BRVO,  branch retinal vein occlusion; NPA,  non-perfusion area;  
DA,  discs area; SRD,  serous retinal detachment.
Fig. 1　 Breakdown of therapeutic processes of all patients during 
the one-year study period.  TAE,  treat-and-extend; ME,  macular 
edema;  PRN,  pro re nata.
for which the mean number of injections and the mean 
number of clinic visits in 1 year were both 7.5 ± 1.8 
(p < 0.001 and p = 0.006,  respectively; unpaired t-test).
For the 4 eyes that demonstrated relapsed ME during 
the PRN period in the TAE to PRN group,  the mean 
number of injections and the mean number of visits 
during the PRN period were 1.0 and 3.5,  respectively.  
The mean number of injections and the mean number 
of visits among these 4 patients during the whole 1 year 
study period were 5.0 and 7.5,  respectively.
For the 19 eyes in the continued TAE group,  the 
distribution of treatment intervals at 1 year is shown in 
Fig. 4.  These treatment intervals ranged from 4 weeks to 
11 weeks,  and the mean treatment interval was 8.1 ± 2.0 
weeks.  The treatment interval was 8 weeks or more for 
12 eyes (63.2%).
The TAE to PRN group and the continued TAE 
group demonstrated significant differences in age,  
BCVA at baseline,  and retinal vein occlusion site (major 
branch retinal vein versus macular branch retinal vein;  
Table 3).  Multiple logistic regression analysis revealed 
that BCVA at baseline and macular BRVO were signifi-
cant predictive factors for switching to PRN (p < 0.026 
and p < 0.025,  respectively; Table 4).
Discussion
The present study demonstrates that a TAE regimen 
of intravitreal ranibizumab injections for treating ME 
due to BRVO effectively improves visual acuity and 
reduces CRT.  Our results are similar to those of a pre-
vious study by Rush et al.,  in which ME due to BRVO 
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Table 2　 Comparison of results at 1 year between the TAE to PRN group and the continued TAE group
Total (n＝35) TAE to PRN (n＝16) Continued TAE (n＝19) P value
BCVA at 1 year (logMAR) 0.09±0.22 0.01±0.11 0.16±0.26 0.047
CRT at 1 year (µm) 271.3±67.7 273.9±85.2 269.0±51.0 0.833
Mean number of injections 6.0±2.1 4.2±0.4 7.5±1.8 ＜0.001
Mean number of visits 6.8±1.6 6.1±0.8 7.5±1.8 0.006
Data are presented as the mean ± standard deviation.
PRN,  pro re nata; TAE,  treat-and-extend regimen; BCVA,  best-corrected visual acuity; logMAR,  logarithm of the minimal angle of reso-
lution; CRT,  central retinal thickness.
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Fig. 2　 Change in visual acuity during the study period.  (a) Visual acuity at baseline and at 1 year.  Scatterplot showing a comparison 
of best-corrected visual acuity at baseline and at 1 year in 35 eyes that underwent intravitreal injections of ranibizumab using a treat-and-
extend regimen.  logMAR,  logarithm of the minimal angle of resolution.  (b) Course of visual acuity.  Graph showing the best-corrected 
visual acuity measured at baseline,  1 month,  6 months and 1 year.  Visual acuity was signiﬁcantly improved at each time point compared 
to baseline.  Error bars represent the standard deviation.  logMAR,  logarithm of the minimal angle of resolution.  (＊) indicates p＜0.01.
was treated with intravitreal bevacizumab injections 
using a TAE regimen [14].  Rush et al.  reported a mean 
change in visual acuity (logMAR) of −0.30 ± 0.20,  with 
59.6% of subjects showing an improvement in visual 
acuity of 0.3 or greater.  These results were similar to 
those reported in the Treatment of Macular Edema fol-
lowing Branch Retinal Vein Occlusion (BRAVO) Study,  
in which ranibizumab was administered PRN following 
monthly injections.  In the BRAVO study,  the mean 
change in visual acuity (logMAR) was −0.37 ± 0.29,  
with 60.3% of subjects showing an improvement in 
visual acuity of 0.3 or greater [1].  In the present study,  
February 2018 Intravitreal Ranibizumab for BRVO 43
Table 3　 Comparison of baseline characteristics between the TAE to PRN group and the continued TAE group
TAE to PRN (n＝16) Continued TAE (n＝19) P value
Age (years) 66.6±12.9 75.1±8.8 0.025
Sex (male/female) 7/9 8/11 0.678
Time period from onset of BRVO to initial injection (months) 2.2±1.9 1.6±1.1 0.346
BCVA at baseline (logMAR) 0.24±0.11 0.55±0.38 0.003
CRT at baseline (µm) 431.1±119.9 457.0±109.1 0.510
Major BRVO/Macular BRVO 6/10 16/3 0.004
NPA≥10DA (eyes (%)) 4 (25.0) 10 (52.6) 0.096
SRD (eyes (%)) 7 (43.8) 8 (42.1) 0.922
Hypertension (eyes (%)) 11 (68.6) 11 (57.9) 0.508
Data are presented as the mean ± standard deviation.
TAE,  treat-and-extend regimen; PRN,  pro re nata; BRVO,  branch retinal vein occlusion; BCVA,  best-corrected visual acuity; CRT,  cen-
tral retinal thickness; NPA,  non-perfusion area; SRD,  serous retinal detachment.
Table 4　 Multiple logistic regression analysis for predictive factors for switching to PRN
95% CI
Covariate Odds ratio P value Lower limit Upper limit
Age 0.901 0.129 0.787 1.031
BCVA (logMAR) at baseline 3.000×10－5 0.026 2.974×10－9 0.295
Major BRVO 14.414 0.025 1.405 147.879
CI,  conﬁdence interval; BCVA,  branch retinal vein occlusion; logMAR,  logarithm of the minimal angle of resolution.
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Fig. 3　 Course of central retinal thickness (CRT).  Graph showing 
CRT at baseline,  1 month,  6 months and 1 year.  CRT was signiﬁ-
cantly improved at each time point compared to baseline.  Error bars 
represent the standard deviation.  logMAR,  logarithm of the minimal 
angle of resolution.  (＊) indicates p＜0.01.
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Fig. 4　 Treatment intervals within the continued TAE group at 1 
year.  Individual patients demonstrated a wide distribution of maxi-
mum treatment intervals,  ranging from 4 to 11 weeks.
we observed visual acuity improvement similar to those 
of Rush et al.  and the BRAVO study,  with a mean 
change in visual acuity (logMAR) of −0.31 ± 0.20 and 
56.9% of subjects showing an improvement in visual 
acuity of 0.3 or greater.
The main advantage of a TAE regimen compared to 
a monthly or a PRN treatment schedule is that the 
number of injections and the number of clinic visits can 
be reduced while maintaining the efficacy of the anti-
VEGF drugs in improving visual acuity.  In the report of 
Rush et al.,  the mean number of injections required 
over 1 year was 8.2,  which is very similar to the mean 
of 8.4 injections presented by the BRAVO study [1 , 14].  
However,  the mean number of required visits to the 
clinic reported by Rush et al.  was 8.2,  which is much less 
than the 12 visits reported by the BRAVO study.  In the 
present study,  the mean number of injections required 
during a 1 year period was 6.0 ± 2.1,  and number of 
clinic visits was 6.8 ± 1.6.  Both of these results are lower 
than those reported by Rush et al.  These differences can 
be explained by the extension of the treatment interval 
to every 2 weeks in the study by Rush et al.,  as opposed 
to every 4 weeks in the present study.  Further studies 
investigating the optimal treatment interval for exten-
sion will be needed in order to reduce the burden on 
both patients and health care providers.
In the present study,  patients whose treatment 
interval was extended to 12 weeks were subsequently 
switched to a PRN regimen (the TAE to PRN group),  
while the TAE regimen was continued for patients 
whose treatment interval was less than 12 weeks (the 
continued TAE group) [14].  The final best corrected 
visual acuity in the TAE to PRN group was significantly 
better than that of the continued TAE group (0.01 ± 0.11 
and 0.16 ± 0.26,  respectively,  p = 0.047; Table 2),  while 
the number of ranibizumab injections in 1 year was sig-
nificantly lower in the TAE to PRN group compared to 
the continued TAE group (4.2 ± 0.4 times,  7.5 ± 1.8 
times,  respectively,  p < 0.001; Table 2).  Indeed,  for all 
16 patients in the TAE to PRN group,  edema improved 
with only a single administration of ranibizumab and 
there was no subsequent relapse before starting a PRN 
regimen.  Additionally,  there was no relapse in 12 of the 
16 eyes (75%) after switching to PRN.  In the 4 eyes 
(25%) for which relapse was observed after switching to 
PRN,  the mean number of injections during the PRN 
duration was only 1.  These results indicate that nearly 
half of the patients with ME due to BRVO (45.7%) 
respond favorably to anti-VEGF therapy and do not 
require frequent anti-VEGF drugs.  Monthly injections 
or a continued TAE regimen for these patients may thus 
have resulted in overtreatment.
Interestingly,  at 1 year the patients in the continued 
TAE group demonstrated diverse maximum treatment 
intervals,  ranging from 4 weeks to 11 weeks (Fig. 4).  In 
the BRAVO study and the Study Evaluating Dosing 
Regimens for Treatment with Intravitreal Ranibizumab 
Injections in Subjects with Macular Edema following 
Retinal Vein Occlusion (SHORE study),  all patients 
underwent a PRN regimen following a 6 month period 
of monthly treatments [1 , 17].  However,  the diversity 
of treatment intervals observed in the present study 
indicates that monthly injections of anti-VEGF drugs 
for patients with little need for them may result in over-
treatment.  For example,  Hikichi et al.  have reported 
that 26% of cases exhibited improvement after only one 
injection over 2 years [18].  In such cases,  monthly 
injections would result in overtreatment.  On the other 
hand,  a PRN regimen for patients with a more signifi-
cant need for anti-VEGF drugs may result in under-
treatment.  For example,  Farinha et al.  have reported 
that PRN treatment improves visual acuity in the short 
term: they observed 13.2 letters of improvement in 
ETDRS visual acuity after 6 months compared to the 
baseline [19].  In the long term,  however,  the improved 
visual acuity could not be maintained.  Two years after 
treatment,  the improvement of visual acuity decreased 
to 6.0 letters compared to the baseline.  Therefore,  con-
tinuation of a TAE regimen may be most effective for 
patients whose treatment interval is less than 12 weeks.
Following multiple logistic regression analysis,  
visual acuity at baseline and the retinal vein occlusion 
site were both found to be associated with inclusion in 
the TAE to PRN group.  In particular,  macular BRVO 
was significantly associated with inclusion in the TAE to 
PRN group (odds ratio = 14.414,  p = 0.025; Table 4).  
The natural history of macular BRVO is separate from 
that of major BRVO,  and amelioration of ME has been 
reported to be achieved earlier in macular BRVO than 
in major BRVO [15].  Moreover,  a PRN regimen of 
anti-VEGF drugs has been shown to lead to a lower 
number of anti-VEGF injections in macular BRVO 
compared to major BRVO [20 , 21].  As reported by 
Noma et al.,  the extent of macular ischemia is greater in 
major BRVO compared to macular BRVO,  resulting in 
increased levels of VEGF and other growth factors as 
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well as inflammatory cytokines,  such as MCP-1 and 
IL-6.  Consequently,  ME is more likely to develop in 
major BRVO [21].
The present study has important limitations,  includ-
ing its retrospective design,  small sample size,  and rel-
atively short study period.  However,  the results of this 
study demonstrate that a TAE regimen of ranibizumab 
injections is effective for improving visual acuity as well 
as for reducing the number of necessary injections in 
the treatment of ME due to BRVO.  In addition,  we 
report that treatment prognosis and frequency varied 
greatly depending on whether or not the treatment 
interval could be extended to 12 weeks.  These results 
indicate that uniform treatment regimens for BRVO,  
such as monthly or PRN injections,  may result in either 
overtreatment or undertreatment.  Further,  when 
determining a TAE anti-VEGF therapy,  a combination 
of TAE with a PRN regimen is effective for patients who 
responded well during the TAE period.  However,  since 
our procedure involves a minimum of four injections,  
the combination of TAE with a PRN regimen may result 
in overtreatment in cases in which the disease does not 
reoccur after one injection [18].  Further randomized 
and controlled clinical studies involving a larger num-
ber of patients are needed to confirm our results.
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